The fact that miR-30d-5p might interfere with ERα signaling further increases its clinical relevance because targeting this pathway is considered to be a promising therapeutic strategy in gynecological cancers (e.g., by the application of antiestrogens, aromatase inhibitors, or by the sustained activation of ERα) [7,64]. Here, CYP19A1 is linked to female reproductive organ cancer.